Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Controlled Study to Investigate the Effect of Either LF111 or Drospirenone Chewable Tablets on Bone Mineral Density (BMD) in Adolescent and Adult Women in Comparison With Non-users of Hormonal Contraceptive Methods

NCT05303636 is registered in ClinicalTrials.gov with Insud Pharma as lead sponsor.

NCT NCT05303636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05303636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Controlled Study to Investigate the Effect of Either LF111 or Drospirenone Chewable Tablets on Bone Mineral Density (BMD) in Adolescent and Adult Women in Comparison With Non-users of Hormonal Contraceptive Methods
Lead sponsor
Insud Pharma
Phase
Phase 4
Overall status
Active, not recruiting
Start date
March 28, 2022
Completion date
June 30, 2028
Enrollment
1,536 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

bone loss, change in bone mineral density